Piper Sandler lowered the firm’s price target on PacBio (PACB) to $1.25 from $2 following quarterly results. The firm keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio board: Independent investigation concludes allegations unsubstantiated
- Pacific Biosciences: Strategic Shift to Long-Read Sequencing Fuels Buy Rating Amid Strong Q1 Performance
- Pacific Biosciences’ Earnings Call: Achievements and Challenges
- Pacific Biosciences’ Strategic Focus on Long-Read Sequencing and International Expansion Drives Growth Potential
- PacBio Reports Q1 2025 Financial Results Amid Restructuring